EMAC2103 | 1245711-18-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: EMAC2103
• 英文别名: 4-(2-(2-Cyclohexylidenehydrazinyl)thiazol-4-yl)benzonitrile；4-[2-(2-cyclohexylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
• CAS: 1245711-18-5
• 化学式: C₁₆H₁₆N₄S
• 分子量: 296.396
• InChiKey: IOWSONKQJRODBA-UHFFFAOYSA-N

物化性质

• 熔点：
  206-207 °C
• 沸点：
  508.7±52.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  89.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (环己亚基氨基)硫脲 在 4-(2-haloacetyl)benzonitrile 作用下， 以 水 为溶剂， 反应 26.0h， 以83%的产率得到EMAC2103
  参考文献：
  名称：

  Exploring the thiazole scaffold for the identification of new agents for the treatment of fluconazole resistant Candida

  摘要：

  Cyclohexyliden- and 2-methylcyclohexyliden-hydrazo-4-arylthiazoles were synthesized and tested as antifungal agents. All compounds exhibited minimal inhibitory concentration (MIC) values comparable with those of fluconazole (FLC). Moreover, some compounds showed fungicidal activity at low concentration. Worth noting five out of nine compounds were active towards Candida albicans 25 FLC resistant isolated from clinical specimens. The cellular toxicity was evaluated and none of the compounds is toxic at the MIC. On the basis of our data we can conclude that these derivatives are promising agents for the treatment of resistant C. albicans.

  DOI：

  10.3109/14756366.2015.1113171

文献信息

• [EN] NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER<br/>[FR] MODULATEURS NAT10 POUR LE TRAITEMENT OU LA PRÉVENTION DES LAMINOPATHIES, DU VIEILLISSEMENT ET DU CANCER
  申请人：CAMBRIDGE ENTPR LTD

  公开号：WO2015150824A1

  公开（公告）日：2015-10-08

  The invention relates to compounds in the treatment or prevention of disorders associated with Lamin A and/or Lamin C depletion or LMNA mutations, such as laminopathy, premature ageing disorders, normal ageing and cancer(such as a cancer characterised by low levels of LMNA expression).

  本发明涉及用于治疗或预防与Lamin A和/或Lamin C耗竭或LMNA突变相关的紊乱的化合物，例如层粘蛋白病，早衰紊乱，正常衰老和癌症（如低水平LMNA表达的癌症）。
• Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors
  作者：Franco Chimenti、Daniela Secci、Adriana Bolasco、Paola Chimenti、Arianna Granese、Simone Carradori、Elias Maccioni、M. Cristina Cardia、Matilde Yáñez、Francisco Orallo、Stefano Alcaro、Francesco Ortuso、Roberto Cirilli、Rosella Ferretti、Simona Distinto、Johannes Kirchmair、Thierry Langer

  DOI：10.1016/j.bmc.2010.05.070

  日期：2010.7

  The present study reports on synthesis in high yields (70-99%), HPLC enantioseparation, inhibitory activity against human monoamino oxidases, and molecular modeling including 3D-QSAR studies, of a large series of (4-aryl-thiazol-2-yl) hydrazones (1-45). Most of the synthesized compounds proved to be potent and selective inhibitors of hMAO-B isoform in the micromolar or nanomolar range, thus demonstrating that hydrazothiazole could be considered a good pharmacophore to design new hMAO-B inhibitors. Due to the presence in some derivatives of a chiral center, we also performed a semipreparative chromatographic enantioseparation of these compounds obtained by a stereoconservative pattern. The separated enantiomers were submitted to in vitro biological evaluation to point out the stereorecognition of the active site of the enzyme towards these structures. Finally, a 3D-QSAR study was carried out using Comparative Molecular Field Analysis (CoMFA), aiming to deduce rational guidelines for the further structural modification of these lead compounds. (C) 2010 Elsevier Ltd. All rights reserved.
• NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER
  申请人：CAMBRIDGE ENTERPRISE LIMITED

  公开号：US20170174644A1

  公开（公告）日：2017-06-22

  The invention relates to compounds in the treatment or prevention of disorders associated with Lamin A and/or Lamin C depletion or LMNA mutations, such as laminopathy, premature ageing disorders, normal ageing and cancer (such as a cancer characterised by low levels of LMNA expression).
• US9809562B2
  申请人：——

  公开号：US9809562B2

  公开（公告）日：2017-11-07
• Exploring the thiazole scaffold for the identification of new agents for the treatment of fluconazole resistant Candida
  作者：Rita Meleddu、Simona Distinto、Angela Corona、Elias Maccioni、Antonella Arridu、Claudia Melis、Giulia Bianco、Peter Matyus、Filippo Cottiglia、Adriana Sanna、Alessandro De Logu

  DOI：10.3109/14756366.2015.1113171

  日期：2016.11.1

  Cyclohexyliden- and 2-methylcyclohexyliden-hydrazo-4-arylthiazoles were synthesized and tested as antifungal agents. All compounds exhibited minimal inhibitory concentration (MIC) values comparable with those of fluconazole (FLC). Moreover, some compounds showed fungicidal activity at low concentration. Worth noting five out of nine compounds were active towards Candida albicans 25 FLC resistant isolated from clinical specimens. The cellular toxicity was evaluated and none of the compounds is toxic at the MIC. On the basis of our data we can conclude that these derivatives are promising agents for the treatment of resistant C. albicans.